Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study

por Tompson, Debra J, Crean, Christopher S, Buraglio, Mauro, Arumugham, Thangam
Publicado 2014

Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug

por Salem, Farzaneh, Nimavardi, Ali, Mudunuru, Jennypher, Tompson, Debra, Bloomer, Jackie, Turner, David B., Taskar, Kunal S.
Publicado 2023

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study

por Schwartzbach, Caryl J., Grove, Richard A., Brown, Robert, Tompson, Debra, Then Bergh, Florian, Arnold, Douglas L.
Publicado 2016

Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A(2) Enzyme Inhibitor Darapladib in Healthy Chinese Subject...

por Hu, Chaoying, Tompson, Debra, Magee, Mindy, Chen, Qian, Liu, Yan Mei, Zhu, Wenjing, Zhao, Hongxin, Gross, Annette S., Liu, Yun
Publicado 2015

Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology

por Tompson, Debra, Whitaker, Mark, Pan, Rennan, Johnson, Geoffrey, Fuller, Teresa, Zann, Vanessa, McKenzie, Litza, Abbott-Banner, Kathy, Hawkins, Simon, Powell, Marcy
Publicado 2022

Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772

por Tompson, Debra J., Whitaker, Mark, Pan, Rennan, Johnson, Geoffrey, Fuller, Teresa, McKenzie, Litza, Zann, Vanessa, Powell, Marcy, Abbott-Banner, Kathy, Hawkins, Simon
Publicado 2021

Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study

por Weisel, Kathleen, Berger, Scott, Papp, Kim, Maari, Catherine, Krueger, James G., Scott, Nicola, Tompson, Debra, Wang, Susanne, Simeoni, Monica, Bertin, John, Peter Tak, Paul
Publicado 2020

A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

por Weisel, Kathleen, Berger, Scott, Thorn, Katie, Taylor, Peter C., Peterfy, Charles, Siddall, Hilary, Tompson, Debra, Wang, Susanne, Quattrocchi, Emilia, Burriss, Susan W., Walter, Jochen, Tak, Paul Peter
Publicado 2021

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects

por Tompson, Debra J., Davies, Carwyn, Scott, Nicola E., Cannons, Edward P., Kostapanos, Michalis, Gross, Annette S., Powell, Marcy, Ino, Hiroko, Shimamura, Ryutaro, Ogura, Hirofumi, Nagakubo, Takashi, Igarashi, Harue, Nakano, Atsushi
Publicado 2020

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

por Weisel, Kathy, Scott, Nicola, Berger, Scott, Wang, Susanne, Brown, Kurt, Powell, Marcy, Broer, Matthijs, Watts, Clarissa, Tompson, Debra J, Burriss, Susan W, Hawkins, Simon, Abbott-Banner, Kathy, Tak, Paul Peter
Publicado 2021

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers

por Weisel, Kathleen, Scott, Nicola E., Tompson, Debra J., Votta, Bartholomew J., Madhavan, Sujith, Povey, Kat, Wolstenholme, Allen, Simeoni, Monica, Rudo, Todd, Richards‐Peterson, Lauren, Sahota, Tarjinder, Wang, J. Gene, Lich, John, Finger, Joshua, Verticelli, Adeline, Reilly, Michael, Gough, Peter J., Harris, Philip A., Bertin, John, Wang, Mei‐Lun
Publicado 2017